Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579077 | 1.00 | CASP3 (0.53) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4468251 | 0.87 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL8950475 | 0.87 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4476083 | 0.87 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL15485550 | 0.84 | CYP1B1 (0.57) | ALDH1A1RCE1 | |
| SCHEMBL29443002 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL30423183 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4581604 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4581609 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL5839893 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) | 2020-03-19 | — | — | US | claimed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
| EP-3154934-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE (FR) | 2021-04-14 | — | — | EP | disclosed |
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) | 2020-03-19 | — | — | US | disclosed |
| US-9828352-B2 | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-11-28 | — | — | US | disclosed |
| EP-3022179-B1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-11-15 | — | — | EP | disclosed |
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-07 | — | — | US | disclosed |
| EP-3022179-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | Fondazione Istituto Italiano Di Tecnologia (IT) | 2016-05-25 | — | — | EP | disclosed |
| US-9260473-B2 | Bivalent multifunctional ligands targeting Aβ oligomers as treatment for Alzheimer's disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-02-16 | — | — | US | disclosed |
| US-4489089-A | INHIBITION OF THE ENZYME THROMBOXANE SYNTHETASE | AMERICAN CYANAMID COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0127727-A2 | Substituted N-(omega-(1H-imidazol-1-yl)alkyl)) amides | AMERICAN CYANAMID COMPANY (US) | 1984-12-12 | — | — | EP | disclosed |
| US-4434174-A | Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1984-02-28 | — | — | US | disclosed |
| EP-0087853-A2 | 4-Diphenylmethyl-1-(oxoalkyl)imino)methyl-piperidines and their derivatives | McNeilab, Inc. (US) | 1983-09-07 | — | — | EP | disclosed |
| US-4370335-A | Antisecretory 4-diphenylmethyl-1-[(oxoalkyl)imino]methyl-piperidines and their derivatives | MCNEILAB, INC. (US) | 1983-01-25 | — | — | US | disclosed |
| US-4363808-A | N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1982-12-14 | — | — | US | disclosed |
| EP-0034116-A2 | N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1981-08-19 | — | — | EP | disclosed |
| US-4211703-A | CHEMICAL INTERMEDIATES FOR CEPHALOSPORINS | SMITHKLINE CORPORATION (US) | 1980-07-08 | — | — | US | disclosed |
| US-4189573-A | CHEMICAL INTERMEDIATES | SMITHKLINE CORPORATION (US) | 1980-02-19 | — | — | US | disclosed |
| US-4112086-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | CASP3 1377/4885CA12 2593/4885CA9 3457/4885 |
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | DRD3, DRD2, PRLHR | CASP3 3659/4885CA12 4782/4885CA9 4879/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | CASP3 1377/4885CA12 2593/4885CA9 3457/4885 |
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FAAH, FAAH2, FFAR3 | CASP3 903/4885CA12 4314/4885CA9 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.